Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
The positron emission tomography (PET) radiotracer Pittsburgh Compound-B (PiB) binds with high affinity to beta-pleated sheet aggregates of the amyloid-beta (Abeta) peptide in vitro. The in vivo retention of PiB in brains of people with Alzheimer's disease shows a regional distribution that is very similar to distribution of Abeta deposits observed post-mortem. However, the basis for regional variations in PiB binding in vivo, and the extent to which it binds to different types of Abeta-containing plaques and tau-containing neurofibrillary tangles (NFT), has not been thoroughly investigated. The present study examined 28 clinically diagnosed and autopsy-confirmed Alzheimer's disease subjects, including one Alzheimer's disease subject who had undergone PiB-PET imaging 10 months prior to death, to evaluate region- and substrate-specific binding of the highly fluorescent PiB derivative 6-CN-PiB. These data were then correlated with region-matched Abeta plaque load and peptide levels, [(3)H]PiB binding in vitro, and in vivo PET retention levels. We found that in Alzheimer's disease brain tissue sections, the preponderance of 6-CN-PiB binding is in plaques immunoreactive to either Abeta42 or Abeta40, and to vascular Abeta deposits. 6-CN-PiB labelling was most robust in compact/cored plaques in the prefrontal and temporal cortices. While diffuse plaques, including those in caudate nucleus and presubiculum, were less prominently labelled, amorphous Abeta plaques in the cerebellum were not detectable with 6-CN-PiB. Only a small subset of NFT were 6-CN-PiB positive; these resembled extracellular 'ghost' NFT. In Alzheimer's disease brain tissue homogenates, there was a direct correlation between [(3)H]PiB binding and insoluble Abeta peptide levels. In the Alzheimer's disease subject who underwent PiB-PET prior to death, in vivo PiB retention levels correlated directly with region-matched post-mortem measures of [(3)H]PiB binding, insoluble Abeta peptide levels, 6-CN-PiB- and Abeta plaque load, but not with measures of NFT. These results demonstrate, in a typical Alzheimer's disease brain, that PiB binding is highly selective for insoluble (fibrillar) Abeta deposits, and not for neurofibrillary pathology. The strong direct correlation of in vivo PiB retention with region-matched quantitative analyses of Abeta plaques in the same subject supports the validity of PiB-PET imaging as a method for in vivo evaluation of Abeta plaque burden.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





![Fig. 6 Correlations of the in vivo PiB DVR values from the 19 VOIs (six of the 25 VOIs had <70% tissue and were not included in the analysis, see Methods section) on the PET scan with post-mortem quantifications of 6-CN-PiB (A) or Aβ (B) plaque load, neurofibrillary load (C) and [3H]PiB binding (D) in the corresponding 19 tissue cubes from the formalin fixed left hemisphere. In vivo PiB-PET retention (DVR) levels correlate directly with regional post-mortem quantitations of 6-CN-PiB (A) and 6E10 (B) plaque loads as well as in vitro PiB binding (D), but not with AT8 neurofibrillary load (C) in formalin-fixed tissue from the left hemisphere. In fresh-frozen tissue from the right hemisphere of the same Alzheimer's disease subject, there is a significant correlation of both in vitro PiB binding (E) and total insoluble Aβ (Aβ1–40 + Aβ1–42) peptide levels (F) with in vivo PiB-PET retention (DVR) levels.](https://figures.cochat.ai/paper-figures/e33db6b5b74a421cb6ab860a36a812a8/post-mortem-correlates-of-in-vivo-pib-pet-amyloid-imaging-in-a-typical-case-of-figure-6.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in accordance with the relative resistance of this region to pathology in mouse AD models and AD patients26”
From Transcriptional signature in microglia associated with Aβ plaque phagocytosis (2021) · cites this paper as [26]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent amyloid imaging techniques have proved an association with Alzheimer disease pathology235 and may prove useful for evaluating the independent and combined effects of vascular and Alzheimer disease brain injury on cognitive changes during normal aging in the future.”
The cited source says what the claim attributes to it.
In the citing paper
“Imaging-to-autopsy comparison studies have established that amyloid positron emission tomography (PET) is a valid in vivo surrogate for Aβ deposits (in brain parenchyma/vessel walls) [17–24].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“the [11C]-benzothiazole radiotracer, Pittsburgh Compound B (PIB), as well as other tracers, can bind to fibrillar Aβ plaques, allowing for visualization of brain amyloid in individuals during positron emission tomography (PET) (23-25).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 3×
“In this case, the final neuropathological diagnosis by CERAD criteria (Mirra et al., 1991) was ‘definite Alzheimer’s disease’, and the Braak stage (Braak and Braak, 1991b) was V/VI.”
BackgroundResultMirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · cited 7×
“…Alzheimer’s disease patients have 2- to 3-fold greater PiB retention on PET scans in brain areas known to have high amounts of fibrillar (i.e. Congo red and thioflavin-S labelled) Ab plaques in Alzheimer’s disease, such as frontal cortex and temporal lobe (Klunk et al., 2004; Price et al., 2005).”
BackgroundInfluentialSelf-citationGauthier, S., Reisberg, B., Zaudig, M., Petersen, R. C., Ritchie, K., Broich, K., Belleville, S., Brodaty, H., Bennett, D., Chertkow, H., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68542-5 · Cited by 3,850
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G. G., & Heyman, A. (2002) · Principles and Practice of Geriatric Psychiatry · doi:10.1002/0470846410.ch42(iii · Cited by 2,410
Simplified Reference Tissue Model for PET Receptor Studies
Lammertsma, A. A., & Hume, S. P. (1996) · NeuroImage · doi:10.1006/nimg.1996.0066 · Cited by 2,021 · cited 1×
“Logan graphical analyses (Logan et al., 1996) were performed for 35–60min (5 points) intervals using input functions derived from cerebellar tissue radioactivity to yield the DVR as the outcome measure (Lammertsma and Hume, 1996).”
MethodIwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774 · cited 1×
“Ab42-containing plaques and Ab42 peptide levels are much more abundant in Alzheimer’s disease brain (Iwatsubo et al., 1994; Naslund et al., 2000), and therefore likely drive the correlation between PiB and total Ab peptide (Ab42 and Ab40 combined) levels as determined in our ELISA assays.”
Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data
Logan, J., Fowler, J. S., Volkow, N. D., Wang, G.-J., Ding, Y.-S., & Alexoff, D. L. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199609000-00008 · Cited by 1,514 · cited 1×
“Logan graphical analyses (Logan et al., 1996) were performed for 35–60min (5 points) intervals using input functions derived from cerebellar tissue radioactivity to yield the DVR as the outcome measure (Lammertsma and Hume, 1996).”
Method
Research works printed but not linked: 2
- Braak, 1991, Neuropathological staging of Alzheimer's disease, Acta Neuropath, 82, 239, 10.1007/BF00308809 · DOI · Paper page
- Kim, 1990, Detection and quantification of β-peptide with two monoclonal antibodies, Neurosci Res Commun, 7, 113
Cited by
Items 301–400 of 963
Zhang, H., Wu, S., & Xing, D. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.09.004 · Cited by 66
Amyloid imaging, Risk Disclosure and Alzheimer’s Disease: Ethical and Practical Issues
Roberts, J. S., Dunn, L. B., & Rabinovici, G. D. (2013) · Neurodegenerative Disease Management · doi:10.2217/nmt.13.25 · Cited by 61
Target-Specific PET Probes for Neurodegenerative Disorders Related to Dementia
Kadir, A., & Nordberg, A. K. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.077164 · Cited by 70
“The strong correlation between in vivo 11C-PIB retention and region-matched quantitative analysis of Ab plaques at autopsy supports the validity of 11C-PIB PET as a method for in vivo evaluation of Ab plaque burden (110).”
BackgroundMethodMallik, A. K., Drzezga, A. E., & Minoshima, S. (2016) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.005 · Cited by 69
Erickson, C. M., Chin, N. A., Johnson, S. C., Gleason, C. E., & Clark, L. R. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12150 · Cited by 76
Seo, S. W., Ayakta, N., Grinberg, L. T., Villeneuve, S., Lehmann, M., Reed, B., DeCarli, C., Miller, B. L., Rosen, H. J., Boxer, A. L., et al. (2017) · NeuroImage: Clinical · doi:10.1016/j.nicl.2016.11.008 · Cited by 63
“Imaging-pathological correlation studies show that in vivo amyloidβ (Aβ) positron emission tomography (PET) strongly predicts the presence of significant Aβ pathology at autopsy (Clark et al., 2012; Curtis et al., 2015; Ikonomovic et al., 2008; Sabri et al., 2015).”
BackgroundInfluentialPositron emission tomographic imaging in drug discovery
Ghosh, K. K., Padmanabhan, P., Yang, C., Ng, D. C. E., Palanivel, M., Mishra, S., Halldin, C., & Gulyás, B. Z. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.07.025 · Cited by 65
Schipke, C. G., Peters, O., Heuser, I., Grimmer, T., Sabbagh, M. N., Sabri, O., Hock, C., Kunz, M., Kuhlmann, J., Reininger, C., et al. (2012) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000339367 · Cited by 64
Huang, S., Li, J., Ye, J., Fleisher, A., Chen, K., Wu, T., & Reiman, E. M. (2012) · IEEE Transactions on Pattern Analysis and Machine Intelligence · doi:10.1109/tpami.2012.129 · Cited by 79
“A possible interpretation is that these are neocortical regions associated with amyloid deposition and early FDG hypometabolism in AD [60], [61], [62], [63], [64], [65].”
BackgroundUmegaki, H. (2009) · Age and Ageing · doi:10.1093/ageing/afp211 · Cited by 70
“Recently, amyloid imaging technology with positron emission tomography, which visualises Aβ depositions in the human brain, has been developed and is now widely available [14] although some limitations of resolution and specificity still exist.”
Amyloid Imaging with PET in Early Alzheimer Disease Diagnosis
Rowe, C. C., & Villemagne, V. L. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.12.017 · Cited by 67
In vitro characterization of [18F]-florbetaben, an Aβ imaging radiotracer
Fodero‐Tavoletti, M. T., Brockschnieder, D., Villemagne, V. L., Martin, L., Connor, A. R., Thiele, A., Berndt, M., McLean, C., Krause, S., Rowe, C. C., et al. (2012) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2012.03.001 · Cited by 65
“This is in agreement with previous observations made for PiB derivatives andmight be related to the high concentration of Aβ fibrils in the core of the plaques [4].”
BackgroundResultLochocki, B., Boon, B. D. C., Verheul, S. R., Zada, L., Hoozemans, J. J. M., Ariese, F., & de Boer, J. F. (2021) · Communications Biology · doi:10.1038/s42003-021-01981-x · Cited by 62
Synapse Stability in the Precuneus Early in the Progression of Alzheimer's Disease
Scheff, S. W., Price, D. A., Schmitt, F. A., Roberts, K. N., Ikonomovic, M. D., & Mufson, E. J. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122353 · Cited by 59
“Although a previous study revealed a strong association between 11C-PiB imaging and fibrillar Aβ deposits, but not neurofibrillary pathology [61], increased 11C-PiB imaging has been shown to associate with a decline in a single episodic memory measure [62].”
Aberrant functional connectivity within the basal ganglia of patients with Parkinson's disease
Rolinski, M., Griffanti, L., Szewczyk‐Królikowski, K., Menke, R., Wilcock, G. K., Filippini, N., Zamboni, G., Hu, M. T. M., & Mackay, C. E. (2015) · NeuroImage Clinical · doi:10.1016/j.nicl.2015.04.003 · Cited by 67
“At face value, thismay seem somewhat surprising given the evidence for basal ganglia involvement in AD from pathophysiological (Ikonomovic et al., 2008) and imaging studies (de Jong et al.”
BackgroundResultInfluentialSubthreshold amyloid and its biological and clinical meaning: Long way ahead
Bischof, G. N., & Jacobs, H. I. L. (2019) · Neurology · doi:10.1212/wnl.0000000000007747 · Cited by 62
In vivo imaging reveals sigmoidal growth kinetic of β-amyloid plaques
Burgold, S., Filser, S., Dorostkar, M. M., Schmidt, B., & Herms, J. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-30 · Cited by 59
Clinical Profile of PiB-Positive Corticobasal Syndrome
Burrell, J. R., Hornberger, M., Villemagne, V. L., Rowe, C. C., & Hodges, J. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061025 · Cited by 58
Integrating ADNI results into Alzheimer's disease drug development programs
Cummings, J. L. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.03.016 · Cited by 59
Tracer Kinetic Analysis of (S)-18F-THK5117 as a PET Tracer for Assessing Tau Pathology
Jonasson, M., Wall, A., Chiotis, K., Saint-Aubert, L., Wilking, H., Sprycha, M., Borg, B., Thibblin, A., Eriksson, J., Sörensen, J., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.158519 · Cited by 58
“The tracer 11C-Pittsburgh compound B (11C-PIB) (1), which binds to fibrillar amyloid (2), was initially introduced for imaging the amyloid plaque load in vivo and followed by development of several other amyloid tracers.”
Backgroundβ-Amyloid 42/40 ratio and kalirin expression in Alzheimer disease with psychosis
Murray, P. S., Kirkwood, C. M., Gray, M. C., Ikonomovic, M. D., Paljug, W. R., Abrahamson, E. E., Henteleff, R. A., Hamilton, R. L., Kofler, J. K., Klunk, W. E., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.02.015 · Cited by 54
Self-citationNordberg, A. (2011) · Alzheimer's Research & Therapy · doi:10.1186/alzrt96 · Cited by 56
In Silico, in Vitro, and in Vivo Evaluation of New Candidates for α-Synuclein PET Imaging
Verdurand, M., Levigoureux, E., Zeinyeh, W., Berthier, L., Mendjel, M., Cadarossanesaib, F., Bouillot, C., Iecker, T., Terreux, R., Lancelot, S., et al. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00229 · Cited by 62
Duara, R., Loewenstein, D., Lizarraga, G., Adjouadi, M., Barker, W., Greig‐Custo, M. T., Rosselli, M., Peñate, A., Shea, Y. F., Behar, R., et al. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.101800 · Cited by 59
“These binary visual ratings have high inter-rater reliability and have been validated by demonstration at postmortem; there is a high correspondence between amyloid burden in PET scans and histopathological and biochemical evidence of amyloid plaques at autopsy (Ikonomovic et al., 2008).”
Self-citationIkonomović, M. D., Buckley, C. J., Abrahamson, E. E., Kofler, J., Mathis, C. A., Klunk, W. E., & Farrar, G. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02175-1 · Cited by 63
Self-citationAβ Imaging: feasible, pertinent, and vital to progress in Alzheimer’s disease
Villemagne, V. L., Klunk, W. E., Mathis, C. A., Rowe, C. C., Brooks, D. J., Hyman, B. T., Ikonomović, M. D., Ishii, K., Jack, C. R., Jagust, W. J., et al. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-2045-0 · Cited by 59
Self-citationPerez, S. E., He, B., Nadeem, M., Wuu, J., Ginsberg, S. D., Ikonomovic, M. D., & Mufson, E. J. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000179 · Cited by 57
“AA ELISA Concentrations of soluble and insoluble AA1Y42 and AA1Y40 peptides were quantified as described previously (61, 66).”
MethodEvolution of Brain Imaging Instrumentation
Abraham, T., & Feng, J. D. (2011) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2010.12.001 · Cited by 57
Cortical phase changes in Alzheimer's disease at 7T MRI: A novel imaging marker
van Rooden, S., Versluis, M. J., Liem, M. K., Milles, J., Maier, A. B., Oleksik, A. M., Webb, A. G., van Buchem, M. A., & van der Grond, J. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.02.002 · Cited by 55
Sex-specific risk of cardiovascular disease and cognitive decline: pregnancy and menopause
Miller, V. M., Garovic, V. D., Kantarci, K., Barnes, J. N., Jayachandran, M., Mielke, M. M., Joyner, M. J., Shuster, L. T., & Rocca, W. A. (2013) · Biology of Sex Differences · doi:10.1186/2042-6410-4-6 · Cited by 63
“Because β-amyloid 140 is the major β-amyloid peptide species within blood vessels, PiB is also sensitive to the β-amyloid associated vasculopathy or cerebral amyloid angiopathy [221].”
BackgroundClark, L. R., Koscik, R. L., Allison, S. L., Berman, S. E., Norton, D., Carlsson, C. M., Betthauser, T. J., Bendlin, B. B., Christian, B. T., Chin, N. A., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.09.008 · Cited by 59
“Two commonly used antemortem biomarkers allowing for early detection of AD-related pathology are [(11)C]PiB positron emission tomography (PET), which allows for imaging of b-amyloid (Ab) plaques in vivo [3], and cerebrospinal fluid (CSF) levels of Ab 1–42 (Ab42), which are correlated with the formation of Ab plaques i…”
BackgroundNeuroimaging in aging and neurologic diseases
Risacher, S. L., & Saykin, A. J. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-12-804766-8.00012-1 · Cited by 82
Imaging Alzheimer's disease pathophysiology with PET
Schilling, L. P., Zimmer, E. R., Shin, M., Leuzy, A., Pascoal, T. A., Benedet, A. L., Borelli, W. V., Palmini, A., Gauthier, S., & Rosa-Neto, P. (2016) · Dementia & Neuropsychologia · doi:10.1590/s1980-5764-2016dn1002003 · Cited by 52
Association of small vessel disease with tau pathology
Kapasi, A., Yu, L., Petyuk, V., Arfanakis, K., Bennett, D. A., & Schneider, J. A. (2022) · Acta Neuropathologica · doi:10.1007/s00401-021-02397-x · Cited by 55
Lazarczyk, M. J., Hof, P. R., Bouras, C., & Giannakopoulos, P. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-127 · Cited by 55
“It is closely correlated with amyloid plaque burden at autopsy [92], and is inversely related to CSF Ab42 levels [75,77,93].”
BackgroundNi, R., Villois, A., Deán‐Ben, X. L., Chen, Z., Vaas, M., Stavrakis, S., Shi, G., deMello, A. J., Ran, C., Razansky, D., et al. (2021) · Photoacoustics · doi:10.1016/j.pacs.2021.100285 · Cited by 58
Amyloid Imaging in Atypical Presentations of Alzheimer’s Disease
Wolk, D. A. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0412-x · Cited by 53
“PET with PiB-C11 has consistently demonstrated the ability to discriminate between cognitively normal adults and patients with AD, predict progression in both preclinical and mild cognitive impairment populations, and correlate the findings with ex vivo histologic measurements of Aβ plaque burden [13–15] (for a review…”
BackgroundMolecular polymorphism of Aβ in Alzheimer's disease
LeVine, H., & Walker, L. C. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.05.026 · Cited by 52
Kawai, N., Kawanishi, M., Kudomi, N., Maeda, Y., Yamamoto, Y., Nishiyama, Y., & Tamiya, T. (2013) · Brain Injury · doi:10.3109/02699052.2013.794963 · Cited by 56
“the retention of (11)C-PIB in vivo correlates well with autopsy measures of Ab deposition in the AD brain [11, 22].”
BackgroundAbbott, A. (2008) · Nature · doi:10.1038/456161a · Cited by 54
Blood protein predictors of brain amyloid for enrichment in clinical trials?
Ashton, N. J., Kiddle, S. J., Graf, J., Ward, M., Baird, A. L., Hye, A., Westwood, S., Wong, K. V., Dobson, R. J., Rabinovici, G. D., et al. (2015) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2014.11.005 · Cited by 54
“(11)C-Pittsburgh compound B (PiB), coupled with positron emission tomography (PET), is widely used in research in measuring in vivo Ab deposition, because its uptake in AD correlates with Ab plaques measured neuropathologically in the same brains [7].”
BackgroundCortical florbetapir-PET amyloid load in prodromal Alzheimer’s disease patients
Saint-Aubert, L., Barbeau, E. J., Péran, P., Nemmi, F., Vervueren, C., Mirabel, H., Payoux, P., Hitzel, A., Bonneville, F., Gramada, R., et al. (2013) · EJNMMI Research · doi:10.1186/2191-219x-3-43 · Cited by 49
“AV-45 shows good correlations with post-mortem lesions [12,13].”
Domínguez-Fernández, C., Egiguren-Ortiz, J., Razquin, J., Gómez-Galán, M., Heras-García, L. D. L., Paredes-Rodriguez, E., Astigarraga, E., Miguélez, C., & Barreda‐Gómez, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043321 · Cited by 60
“assay, the analysis of data, and the reporting of results [52].”
MethodRevision of the criteria for Alzheimer's disease: A symposium
DeKosky, S. T., Carrillo, M. C., Phelps, C., Knopman, D., Petersen, R. C., Frank, R., Schenk, D., Masterman, D., Siemers, E. R., Cedarbaum, J. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.12.007 · Cited by 51
“Available and in use in more than 60 sites around the world, PiB is a neutral derivative of the dye thioflavin T, used in pathology studies of amyloid plaque at autopsy, and the most extensively studied amyloid ligand, including quantitative correlation in post mortem brain following PiB PET scan during life [73].”
BackgroundSelf-citationSabbagh, M. N. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.535 · Cited by 52
“Both visual reads and quantitative binding measures were consistent with amyloid seen on pathology.(10,15) Quantification of florbetapir PET was useful even when using a cerebellar reference region found to have elevated florbetapir uptake and neuropathologic evidence of diffuse plaques and vascular amyloid compared w…”
Banning, L. C. P., Ramakers, I. H. G. B., Deckers, K., Verhey, F. R. J., & Aalten, P. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.09.014 · Cited by 54
Koychev, I. G., Hofer, M., & FRIEDMAN, N. C. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.230458 · Cited by 58
“Specific biomarker targets for neuritic plaque have not been identified, but Ab tracers have been shown to have affinity for both diffuse Ab and neuritic plaques (19,34), because the substrate for all known tracers is the b-pleated sheet conformation of fibrillary Ab (19).”
BackgroundAmyloid imaging in dementias with atypical presentation
Wolk, D. A., Price, J. C., Madeira, C., Saxton, J. A., Snitz, B. E., Lopez, O. L., Mathis, C. A., Klunk, W. E., & DeKosky, S. T. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.07.003 · Cited by 49
“Twenty-eight patients with an atypical or a focal form of dementia (mean: 64.6 6 10.3 [SD] years; 14 females) were recruited for PiB PET imaging.”
ResultInfluentialSelf-citationLiu, C., Chyr, J., Zhao, W., Xu, Y., Ji, Z., Tan, H., Soto, C. A., Zhou, X., & Initiative, A. D. N. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00410 · Cited by 55
“There is evidence showing that HSV infection in AD brains was observed (Itzhaki and Wozniak, 2008).”
BackgroundA metabolomic approach to identifying biomarkers in blood of Alzheimer's disease
Lin, C., Huang, C., Huang, K., Lin, K., Yen, T., & Kuo, H. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.726 · Cited by 57
Functional brain imaging of cognitive dysfunction in Parkinson's disease
Hirano, S., Shinotoh, H., & Eidelberg, D. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-301818 · Cited by 55
Racine, A. M., Merluzzi, A. P., Adluru, N., Norton, D., Koscik, R. L., Clark, L. R., Berman, S. E., Nicholas, C. R., Asthana, S., Alexander, A. L., et al. (2019) · Brain Imaging and Behavior · doi:10.1007/s11682-017-9732-9 · Cited by 47
“…(AD) is a progressive neurodegenerative disorder characterized by several hallmark pathologies, including extracellular deposition of beta-amyloid (Aβ) plaques (Klunk et al. 2004; Nordberg 2004; Ikonomovic et al. 2008), and intracellular aggregation of hyper-phosphorylated tau (Alonso et al. 1996).”
BackgroundBenussi, A., Alberici, A., Ferrari, C., Cantoni, V., Dell’Era, V., Turrone, R., Cotelli, M. S., Binetti, G., Paghera, B., Koch, G., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0423-6 · Cited by 50
Dementia spectrum disorders: lessons learnt from decades with PET research
Wilson, H., Pagano, G., & Politis, M. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-01975-4 · Cited by 47
Schreiber, S., Wilisch-Neumann, A., Schreiber, F., Assmann, A., Scheumann, V., Perosa, V., Jandke, S., Mawrin, C., Carare, R. O., & Werring, D. J. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12576 · Cited by 55
Neuroimaging of Alzheimer’s disease: focus on amyloid and tau PET
Matsuda, H., Shigemoto, Y., & Sato, N. (2019) · Japanese Journal of Radiology · doi:10.1007/s11604-019-00867-7 · Cited by 52
White matter abnormalities are key components of cerebrovascular disease impacting cognitive decline
Vemuri, P., Graff‐Radford, J., Lesnick, T. G., Przybelski, S. A., Reid, R. I., Reddy, A. L., Lowe, V. J., Mielke, M. M., Machulda, M. M., Petersen, R. C., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab076 · Cited by 53
“We used amyloid-PET imaging using (11)C-labeled Pittsburgh Compound-B-PET as a surrogate for cerebral amyloidosis.(13)”
MethodCerebral perfusion alterations and cerebral amyloid in autosomal dominant Alzheimer disease
McDade, E., Kim, A., James, J., Sheu, L. K., Kuan, D. C.-H., Minhas, D., Gianaros, P. J., Ikonomovic, S., Lopez, O., Snitz, B., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000721 · Cited by 48
Self-citationRadiolabeled bioactive benzoheterocycles for imaging β-amyloid plaques in Alzheimer's disease
Yang, Y., & Cui, M. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.10.012 · Cited by 51
Cerebral Amyloidosis: Postmortem Detection with Human 7.0-T MR Imaging System
van Rooden, S., Maat-Schieman, M. L. C., Nabuurs, R. J. A., van der Weerd, L., van Duijn, S., van Duinen, S. G., Natté, R., van Buchem, M. A., & van der Grond, J. (2009) · Radiology · doi:10.1148/radiol.2533090490 · Cited by 49
Relationship between Plasma Analytes and SPARE-AD Defined Brain Atrophy Patterns in ADNI
Toledo, J. B., Da, X., Bhatt, P., Wolk, D. A., Arnold, S. E., Shaw, L. M., Trojanowski, J. Q., Davatzikos, C., & Initiative, A. D. N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055531 · Cited by 49
“While repeated measurements of CSF Ab as well as PIB PET Ab plaque burden in AD patients have not been shown to change further with the progression of AD [99,100,101,102], t-tau CSF levels have been reported to increase as AD progresses over time [99,102] thereby suggesting that the CSF T-tau/Ab42 ratio could increase…”
BackgroundImaging Frontotemporal Lobar Degeneration
Diehl‐Schmid, J., Onur, O. A., Kuhn, J., GRUPPE, T. L., & Drzezga, A. E. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0489-x · Cited by 52
Longitudinal imaging of the ageing mouse
Dall’Ara, E., Boudiffa, M., Taylor, C., Schug, D., Fiegle, E., Kennerley, A. J., Damianou, C., Tozer, G. M., Kiessling, F. M., & Müller, R. (2016) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.08.001 · Cited by 52
Down syndrome, beta-amyloid and neuroimaging
Head, E., Helman, A. M., Powell, D., & Schmitt, F. A. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.09.013 · Cited by 47
Long, J. M., Coble, D. W., Xiong, C., Schindler, S. E., Perrin, R. J., Gordon, B. A., Benzinger, T. L. S., Grant, E., Fagan, A. M., Harari, O., et al. (2022) · Brain · doi:10.1093/brain/awac250 · Cited by 52
Pontecorvo, M. J., & Mintun, M. A. (2011) · Alzheimer's Research & Therapy · doi:10.1186/alzrt70 · Cited by 48
Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes
Tan, R. H., Kril, J. J., Yang, Y., Tom, N., Hodges, J. R., Villemagne, V. L., Rowe, C. C., Leyton, C. E., Kwok, J. B. J., Ittner, L. M., et al. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.05.005 · Cited by 48
“As such, althoughwe only identified a strong regional correlation with SUVR scaled to white matter, future studies in larger cohorts or sampling greater predilection sites will determine if histological Ab correlates with SUVR scaled to the cerebellum in FTD, as seen in AD [4].”
BackgroundNeuroimaging Results Impose New Views on Alzheimer’s Disease—the Role of Amyloid Revised
Fjell, A. M., & Walhovd, K. B. (2011) · Molecular Neurobiology · doi:10.1007/s12035-011-8228-7 · Cited by 51
Zha, Z., Choi, S., Plöessl, K., Lieberman, B. P., Qü, W., Hefti, F. F., Mintun, M. A., Skovronsky, D., & Kung, H. F. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2009106 · Cited by 51
Perez, S. E., He, B., Nadeem, M., Wuu, J., Scheff, S. W., Abrahamson, E. E., Ikonomovic, M. D., & Mufson, E. J. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.12.016 · Cited by 47
Self-citationImaging the Role of Amyloid in PD Dementia and Dementia with Lewy Bodies
Gomperts, S. N. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0472-6 · Cited by 47
Perez, S. E., Miguel, J. C., He, B., Malek-Ahmadi, M., Abrahamson, E. E., Ikonomovic, M. D., Lott, I., Doran, E., Alldred, M. J., Ginsberg, S. D., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01965-6 · Cited by 49
“Sections were rinsed in KPBS, incubated in 100 µM X-34 for 10 min, dipped in tap water, and incubated in 0.2% NaOH made with 80% EtOH [49] or incubated in 10 µM 6-CN-PiB for 45 min, dipped three times in KPBS followed by a 1-min differentiation in KPBS [50].”
InfluentialSelf-citationZhang, H., Wu, S., & Xing, D. (2011) · APOPTOSIS · doi:10.1007/s10495-011-0608-y · Cited by 49
Neuropathological correlates of amyloid PET imaging in Down syndrome
Abrahamson, E. E., Head, E., Lott, I. T., Handen, B. L., Mufson, E. J., Christian, B. T., Klunk, W. E., & Ikonomovic, M. D. (2019) · Developmental Neurobiology · doi:10.1002/dneu.22713 · Cited by 45
“Multiple studies of AD, MCI, and aged non‐demented controls demonstrated high correspondence between postmortem amyloid pathology and antemortem amyloid PET imaging using [C‐11]PiB (Bacskai et al., 2007; Burack et al., 2010; Ikonomovic et al., 2008; Kadir et al., 2011; Kantarci et al., 2012; Sojkova et al., 2011) and…”
MethodSelf-citationBird, S. M., Sohrabi, H. R., Sutton, T. A., Weinborn, M., Rainey-Smith, S. R., Brown, B., Patterson, L., Taddei, K., Gupta, V., Carruthers, M., et al. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.01.004 · Cited by 44
Brain amyloidosis ascertainment from cognitive, imaging, and peripheral blood protein measures
Apostolova, L. G., Hwang, K. S., Avila, D., Elashoff, D., Kohannim, O., Teng, E., Sokolow, S., Jack, C. R., Jagust, W. J., Shaw, L., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001231 · Cited by 44
Self-citationLowe, V. J., Lundt, E., Knopman, D., Senjem, M. L., Gunter, J. L., Schwarz, C. G., Kemp, B. J., Jack, C. R., & Petersen, R. C. (2017) · NeuroImage: Clinical · doi:10.1016/j.nicl.2017.08.011 · Cited by 45
“Diffuse plaque has been shown to have less intense PiB-PET signal (Ikonomovic et al., 2008).”
Lochocki, B., Morrema, T. H. J., Ariese, F., Hoozemans, J. J. M., & de Boer, J. F. (2020) · The Analyst · doi:10.1039/c9an02087j · Cited by 47
Biomarkers for Predicting Cognitive Decline in those with Normal Cognition
Steenland, K., Initiative, A. D. N., Zhao, L., Goldstein, F. C., Cellar, J. S., & Lah, J. J. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-2014-131343 · Cited by 48
Disclosure of amyloid imaging results to research participants: Has the time come?
Lingler, J. H., & Klunk, W. E. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.09.014 · Cited by 46
Self-citationLi, H.-C., Chen, P., Cheng, H.-F., Kuo, Y., & Huang, C. (2019) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2019.2904702 · Cited by 45
“Several medical imaging modalities have been used for diagnosing AD, such as computed tomography, magnetic resonance imaging (MRI), and positron emission tomography (PET) [14], [15].”
MethodMichno, W., Stringer, K. M., Enzlein, T., Passarelli, M. K., Escrig, S., Vitanova, K. S., Wood, J. I., Blennow, K., Zetterberg, H., Meibom, A., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg4855 · Cited by 54
Leinonen, V., Rinne, J. O., Virtanen, K. A., Eskola, O., Rummukainen, J., Huttunen, J., von und zu Fraunberg, M., Nerg, O., Koivisto, A. M., Rinne, J., et al. (2013) · European Journal of Neurology · doi:10.1111/ene.12102 · Cited by 42
“The degree of [(11)C]PiB uptake in the cerebral cortex measured with positron emission tomography (PET) in living patients correlates with fibrillar amyloid-b levels in brain tissue measured subsequently at post mortem, as has been demonstrated by HC and IHC analyses of brain tissue samples [6,12].”
BackgroundSala, A., Nordberg, A. K., Rodriguez‐Vieitez, E., & Initiative, A. D. N. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-00950-w · Cited by 47
Chen, C.-J., Bando, K., Ashino, H., Taguchi, K., Shiraishi, H., Shima, K., Fujimoto, O., Kitamura, C., Matsushima, S., Uchida, K., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.146944 · Cited by 43
“The correlation between PiB binding and the amounts of either A(1-40) or A(1-42) was not significant (20), being attributable to preferential binding of PiB to certain A subtypes, such as AN3(pE) (2).”
BackgroundMethodInfluentialMi, Z., Halfter, W. M., Abrahamson, E. E., Klunk, W. E., Mathis, C. A., Mufson, E. J., & Ikonomović, M. D. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw062 · Cited by 43
“This might be due to lesser microgliosis associated with CAA-burdened vessels compared with cored plaques (39, 40) and decreased ECM proteins; the latter may possibly relate to their susceptibility to rupture (41).”
BackgroundInfluentialSelf-citationDiagnostic biomarkers in Alzheimer’s disease
Andersen, E., Casteigne, B., Chapman, W. D., Creed, A., Foster, F., Lapins, A., Shatz, R., & Sawyer, R. P. (2021) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2021.100041 · Cited by 42
Alzheimer’s Amyloid Hypothesis and Antibody Therapy: Melting Glaciers?
Høilund‐Carlsen, P. F., Alavi, A. A., Castellani, R. J., Neve, R. L., Perry, G. L., Revheim, M.-E. R., & Barrio, J. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073892 · Cited by 47
Sarazin, M., Lagarde, J., Haddad, I., de Souza, L. C., Bellier, B., Potier, M., Bottlaender, M., & Dorothée, G. (2024) · Nature Aging · doi:10.1038/s43587-024-00630-2 · Cited by 46
Shokouhi, S., Mckay, J. W., Baker, S. L., Kang, H., Brill, A. B., Gwirtsman, H. E., Riddle, W. R., Claassen, D. O., Rogers, B. P., & Initiative, A. D. N. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0172-3 · Cited by 45
Differences in Aβ brain networks in Alzheimer's disease and healthy controls
Duan, H., Jiang, J., Xu, J. L., Zhou, H., Huang, Z., Yu, Z., & Yan, Z. (2016) · Brain Research · doi:10.1016/j.brainres.2016.11.019 · Cited by 46
Recent progress in the development of metal complexes as β-amyloid imaging probes in the brain
Chen, K.-H., & Cui, M. (2017) · MedChemComm · doi:10.1039/c7md00064b · Cited by 44
Ni, R., Röjdner, J., Voytenko, L. P., Dyrks, T., Thiele, A., Marutle, A., & Nordberg, A. K. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201344 · Cited by 44
Dugger, B. N., Serrano, G. E., Sue, L. I., Walker, D. G., Adler, C. H., Shill, H. A., Sabbagh, M. N., Caviness, J. N., Hidalgo, J., Saxon-LaBelle, M., et al. (2012) · Journal of Parkinson’s Disease · doi:10.3233/jpd-2012-11073 · Cited by 41
“It also appears likely, based on postmortem autoradiography studies with antemortem amyloid imaging, that all types of Aβ amyloid, including diffuse, cored and neuritic plaques as well as amyloid angiopathy, will elicit strong amyloid imaging signals [61,63,64].”
Early risk assessment for Alzheimer's disease
Carrillo, M. C., Blackwell, A. D., Hampel, H. J., Lindborg, J., Sperling, R. A., Schenk, D., Sevigny, J., Ferris, S. H., Bennett, D. A., Craft, S., et al. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.01.019 · Cited by 43
“For example, the process of learning CSF or imaging results, particularly PET amyloid imaging, could parallel that observed for the APOE results in the REVEAL Study.”
BackgroundInfluentialSelf-citation2023 China Alzheimer’s disease: facts and figures
Xiao, J., Li, J., Wang, J., Zhang, X., Wang, C., Peng, G., Hu, H., Liu, H., Liu, J., Shen, L., et al. (2023) · Human Brain · doi:10.37819/hb.3.1771 · Cited by 47
MicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research
Zimmer, E. R., Parent, M. J., Cuello, A. C., Gauthier, S. G., & Rosa‐Neto, P. (2014) · Trends in Neurosciences · doi:10.1016/j.tins.2014.07.002 · Cited by 47
Teng, E., Kepe, V., Frautschy, S. A., Liu, J., Satyamurthy, N., Yang, F., Chen, P.-P., Cole, G. B., Jones, M. R., Huang, S.-C., et al. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.05.003 · Cited by 41
Brain tissue Aβ42 levels are linked to shunt response in idiopathic normal pressure hydrocephalus
Hamdeh, S. A., Virhammar, J., Sehlin, D., Alafuzoff, I. I., Cesarini, K. G., & Marklund, N. (2018) · Journal of neurosurgery · doi:10.3171/2017.7.jns171005 · Cited by 48
Filippi, L., Chiaravalloti, A., Bagni, O., & Schillaci, O. (2018) · Europe PMC (PubMed Central) · Cited by 51
Metadata
- Authors
- Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., Debnath, M. L., Hope, C. E., Isanski, B. A., Hamilton, R. L., & DeKosky, S. T.
- Affiliations
- University of Pittsburgh (US)
- Corresponding author
- DeKosky, Steven T.
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-03-12
- Volume
- 131
- Issue
- 6
- Pages
- 1630-1645
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC2408940
- OpenAlex
- W2156981442
- Cited by
- 933
- References
- 66
- Citations by year
- 2026: 16 · 2025: 24 · 2024: 29 · 2023: 25 · 2022: 33 · 2021: 42 · 2020: 44 · 2019: 56 · 2018: 51 · 2017: 46 · 2016: 58 · 2015: 57 · 2014: 82 · 2013: 81 · 2012: 79
- FWCI
- 47.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Brain (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion, public-domain)
- Funders
- U.S. Department of Energy (FG02-03ER63590, DE-FD02-03 ER63590, ER63590, DE-FD02-03)
- Alzheimer's Association (AG14449, TLL-01-3381)
- University of Pittsburgh (AG05133)
- National Institute for Health and Care Research
- National Institutes of Health (AG05133, AG025204, AG14449, AG025516)
- National Institute on Aging (AG 05-133, R01AG018402, P01AG025204, RF1AG025516, P50AG005133, P01AG014449, R01AG020226, AG025516, K02AG001039, P01 AG14449, P50-AG-05133, R37AG025516, R01AG025516)
- National Institute of Mental Health (R01MH070729, K01MH001976)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- Alzheimer's disease, amyloid plaques, Pittsburgh compound B, neurofibrillary tangles, tau protein, postmortem brain, amyloid-beta 42, Aβ40, vascular amyloid deposits, prefrontal cortex, temporal cortex, cerebellum
- MeSH terms
- Alzheimer Disease, Aniline Compounds, Autopsy, Brain, Carbon Radioisotopes, Enzyme-Linked Immunosorbent Assay, Female, Humans, Image Interpretation, Computer-Assisted, Immunohistochemistry, Magnetic Resonance Imaging, Middle Aged, Thiazoles, Reproducibility of Results, Amyloid beta-Peptides, Neurofibrillary Tangles, tau Proteins, Positron-Emission Tomography, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.